A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

- Men or women 18 years or older with histologically or cytologically confirmed advanced non-squamous NSCLC (unresectable stage IIIB with pericardial or pleural effusion or stage IV/recurrent) - Measureable disease per RECIST criteria modified - ECOG performance status of 0 or 1 - Ability to take oral medications - Competent to give written informed consent

- Current or prior history of CNS metastases - Any prior chemotherapy for advanced NSCLC - History of pulmonary hemorrhage or gross hemoptysis within 6 months prior to randomization - Prior targeted therapies - Known history of allergy or hypersensitivity to paclitaxel or carboplatin - History of arterial or venous thrombosis within 52 weeks prior to randomization - History of bleeding diathesis or non-pulmonary bleeding within 14 days prior to randomization - Peripheral neuropathy > grade 1 per CTCAE Version 3.0 - Myocardial infarction, cerebrovascular accident, grade 2 or greater peripheral vascular disease, transient ischemic attack, congestive heart failure, percutaneous transluminal coronary angioplasty/stent, ongoing arrythmias requiring medication or unstable angina within 52 weeks prior to randomization - Any kind of disorder that compromises the ability of the subject to comply with the study procedures -Uncontrolled hypertension as defined by resting blood pressure > 150/90 mm Hg. Anti-hypertensive medications are allowed if hypertension is stably controlled at the time of randomization. - Participation in therapeutic clinical trials or currently receiving other investigational treatment(s) within 30 days prior to randomization - Pregnant or breast feeding women - Known to be HIV, hepatitis B surface antigen, or hepatitis C positive